Seelos Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 73.53 million compared to USD 66.05 million a year ago. Basic loss per share from continuing operations was USD 20.7 compared to USD 21.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | +4.51% | -14.72% | -87.50% |
05-16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
05-14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
1st Jan change | Capi. | |
---|---|---|
-87.50% | 3.47M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- SEEL Stock
- News Seelos Therapeutics, Inc.
- Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022